• IV: Ventricular arrhythmias.

Local:

• Infiltration/mucosal/topical anesthetic.
• Topical: Pain due to post-herpetic neuralgia.

Contraindicated in:

• Hypersensitivity; cross-sensitivity may occur
• Third-degree heart block
• Wolff-Parkinson-White syndrome
• Pedi: Children <3 yr (↑ risk of seizures, cardiac arrest and death with viscous lidocaine); viscous lidocaine should not be used for teething pain; should only be used for other indications when safer alternatives are not available or have failed.

Use Cautiously in:

• Glucose–6–phosphate dehydrogenase deficiency, history of methemoglobinemia, cardiac or pulmonary disease, or concurrent exposure to oxidizing agents (or metabolites of these agents) (↑ risk of methemoglobinemia)
• Liver disease, HF, patients weighing <50 kg, and geriatric patients (↓ bolus and/or maintenance dose)
• Respiratory depression
• Shock
• Heart block
• OB: Lactation: Use only if the potential benefit justifies the potential risk to the fetus
• Pedi: Infants <6 mo (↑ risk of methemoglobinemia); safety of topical patch not established in children.

CV: arrhythmias, bradycardia, CARDIAC ARREST, heart block, hypotension.

EENT: mucosal use: ↓or absent gag reflex.

GI: nausea, vomiting.

Hemat: methemoglobinemia.

Local: stinging, burning, contact dermatitis, erythema.

MS: chondrolysis.

Neuro: confusion, drowsiness, agitation, blurred vision, dizziness, paresthesia, SEIZURES, slurred speech, tremor.

Resp: bronchospasm.
Misc: (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS .

Drug-Drug:

• Concurrent use of acetaminophen, benzocaine, bupivacaine, chloroquine, cyclophosphamide, dapsone, flutamide, hydroxyurea, ifosfamide, metoclopramide, nitrofurantoin, nitroglycerin, nitroprusside, nitrous oxide, phenobarbital, phenytoin, prilocaine, primaquine, procaine, quinine, rasburicase, ropivacaine, sulfonamides, tetracaine, and valproate may ↑ risk of methemoglobinemia; monitor closely.
• ↑cardiac depression and toxicity with phenytoin, amiodarone, quinidine, procainamide, or propranolol.
• Cimetidine, azole antifungals, clarithromycin, erythromycin, fluoxetine, fluvoxamine, nefazodone, paroxetine, protease inhibitors, propofol, ritonavir, verapamil, and propranolol may ↓ metabolism and ↑ risk of toxicity.
• Lidocaine may ↑ levels of calcium channel blockers, certain benzodiazepines, cyclosporine, fluoxetine, lovastatin, simvastatin, mirtazapine, paroxetine, ritonavir, tacrolimus, theophylline, tricyclic antidepressants, and venlafaxine.
• Effects of lidocaine may be ↓ by carbamazepine, phenobarbital, phenytoin, and rifampin.

(Generic available)

• Solution for injection: 5 mg/mL (0.5%); 10 mg/mL (1%); 15 mg/mL (1.5%); 20 mg/mL (2%);
• Premixed infusion: 1000 mg/250 mL D5W (0.4%); 2000 mg/500 mL D5W (0.4%); 2000 mg/250 mL D5W (0.8%);
• Injection for local infiltration/nerve block: 0.5%; 1%; 2%; 4%;
• Topical cream: 4%^OTC; 5%;
• Topical gel: 2%^OTC; 3%; 4%; 5%^OTC;
• Topical jelly: 2%;
• Topical liquid: 2.5%;
• Topical ointment: 4%; 5%;
• Topical patch: 1.8%; 3.5%; 4%; 5%;
• Topical solution: 2%; 4%;
• Topical spray: 2%; 4%;
• Viscous solution: 2%;
• In combination with: diclofenac (Diclona); epinephrine (Xylocaine with Epinephrine); prilocaine (Oraquix).

Ventricular Tachycardia (with a Pulse) or Pulseless Ventricular Tachycardia/Ventricular Fibrillation

• IV (Adults): 1–1.5 mg/kg bolus; may repeat doses of 0.5–0.75 mg/kg every 5–10 min up to a total dose of 3 mg/kg; may then start continuous infusion of 1–4 mg/min.
• Endotracheal (Adults): Give 2–2.5 times the IV loading dose down the endotracheal tube, followed by a 10 mL saline flush.
• IV (Children): 1 mg/kg bolus (not to exceed 100 mg), followed by 20–50 mcg/kg/min continuous infusion (range 20–50 mcg/kg/min); may administer 2nd bolus of 0.5–1 mg/kg if delay between bolus and continuous infusion.
• Endotracheal (Children): Give 2–3 mg/kg down the endotracheal tube followed by a 5 mL saline flush.

Local

• Infiltration (Adults and Children): Infiltrate affected area as needed (increased amount and frequency of use increases likelihood of systemic absorption and adverse reactions).
• Topical (Adults): Cream/ointment/gel/solution/jelly: Apply to affected area 2–3 times daily. Patch: Up to 3 patches may be applied once for up to 12 hr in any 24-hr period; consider smaller areas of application in geriatric or debilitated patients.
• Mucosal (Adults): For anesthetizing oral surfaces: 20 mg as 2 sprays/quadrant (not to exceed 30 mg/quadrant) may be used. 15 mL of the viscous solution may be used every 3 hr for oral or pharyngeal pain. For anesthetizing the female urethra: 3–5 mL of the jelly or 20 mg as 2% solution may be used. For anesthetizing the male urethra: 5–10 mL of the jelly or 5–15 mL of 2% solution may be used before catheterization or 30 mL of jelly before cystoscopy or similar procedures. Topical solutions may be used to anesthetize mucous membranes of the larynx, trachea, or esophagus.
• Mucosal (Children 3 yr): Do not exceed 4.5 mg/kg/dose (or 300 mg/dose) of viscous solution; swish in the mouth and spit out no more frequently than every 3 hr (maximum: 4 doses per 12-hr period).
• Mucosal (Children <3 yr): 1.2 mL applied to area with a cotton-tipped applicator no more frequently than every 3 hr (maximum: 4 doses per 12-hr period); use only if the underlying condition requires treatment with product volume of 1.2 mL.

lidocaine (Parenteral): Xylocaine

lidocaine (Local Anesthetic): Xylocaine

lidocaine (Mucosal): Xylocaine Viscous

lidocaine (Topical): Glydo, Lidoderm, L-M-X 4, L-M-X 5, Xylocaine, ZTLido

• IV: Suppresses automaticity and spontaneous depolarization of the ventricles during diastole by altering the flux of sodium ions across cell membranes with little or no effect on heart rate.
• .
  Local: Produces local anesthesia by inhibiting transport of ions across neuronal membranes, thereby preventing initiation and conduction of normal nerve impulses.

• Control of ventricular arrhythmias.
• Local anesthesia.

Therapeutic Classification: anesthetics (topical/local), antiarrhythmics (class IB)

Absorption: IV administration results in complete bioavailability; some absorption follows local use.

Distribution: Widely distributed. Concentrates in adipose tissue. Crosses the blood-brain barrier.

Metabolism/Excretion: Mostly metabolized by the liver; <10% excreted in urine as unchanged drug.

Half-life: Biphasic — initial phase, 7–30 min; terminal phase, 90–120 min; ↑ in HF and hepatic impairment.

lidocaine (Parenteral): Xylocard

lidocaine (Mucosal): Jampocaine Viscous

lidocaine (Topical): Betacaine, Cathejell, Lidodan, Lyracaine, Maxilene, Stallion, Topicaine

(IV = antiarrhythmic effects; local = anesthetic effects)

• Explain purpose of lidocaine to patient.
• May cause drowsiness and dizziness. Advise patient to call for assistance during ambulation and transfer.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.
• Topical: Apply Lidoderm Patch to intact skin to cover the most painful area. Patch may be cut to smaller sizes with scissors before removing release liner. Clothing may be worn over patch. Avoid contact with water (bathing, swimming, showering), may not stick if it gets wet. If irritation or burning sensation occurs during application, remove patch until irritation subsides. Wash hands after application; avoid contact with eyes. Dispose of used patch to avoid access by children or pets.
  • Apply ZTLido to intact skin to cover the most painful area. Apply immediately after removing from envelope. System may be cut to smaller sizes with scissors before removing release liner. Clothing may be worn over patch. May be used during moderate exercise (biking for 30 min). May be exposed to water (showering for 10 min or immersion for 15 min). Dry by gently patting the skin, not by rubbing skin or topical system. If edges have lifted, press firmly on edges. If system detaches, may be reapplied as originally directed. If system will not stick, dispose by folding adhesive sides together and discard where children or pets cannot get to them. Apply a new system for total duration of 12 hr of used and new system together. If irritation or a burning sensation occurs during application, remove and reapply when irritation subsides.
  • Caution women to consult health care professional before using a topical anesthetic for a mammogram or other procedures. If recommended, use lowest drug concentration, and apply sparingly. Do not apply to broken or irritated skin, do not wrap skin, and do not apply heat to area (heating pad/electric blanket), to decrease chance that drug may be absorbed into the body. May result in seizures, cardiac arrhythmias, respiratory failure, coma, and death.
  • Advise patient referred for MRI test to discuss patch with referring health care professional and MRI facility to determine if removal of patch is necessary prior to test and for directions for replacing patch.
• Mucosal: Caution parent to administer as directed, not to use more or more often than directed, and to use measuring device for accurate dose in children younger than 3 yr. Advise parent that if signs and symptoms of toxicity (lethargy, shallow breathing, seizure activity) occur to seek emergency attention and not to administer more lidocaine.
  • Caution parents that oral lidocaine causes numbness and may impair swallowing; do not administer food and/or chewing gum for at least 60 min after administration.

lidocaine (Parenteral): LYE-doe-kane